Literature DB >> 8362528

Surgical treatment of the Zollinger-Ellison syndrome.

F Stadil1, L Bardram, J Gustafsen, F Efsen.   

Abstract

A consecutive series of patients with Zollinger-Ellison syndrome (ZES) is reported. A total of 53 cases were diagnosed, treated, and followed by one department during the period 1971-1990. Curative surgery was considered in all cases after suppression of acid secretion and after localization of the tumors. Exploratory laparotomy was not employed. Of the 53 patients 13 (24%) died from metastatic gastrinoma during the study. Tumors were ultimately located in 31 of the patients, and 21 of these patients were operated. A total of 12 patients (21%) were cured. The best results were obtained after Whipple pancreaticoduodenectomy in patients with small tumors located after percutaneous transhepatic portography with blood sampling for gastrin assay. In this group 9 of 10 operated patients were cured. Multiple endocrine neoplasia type I did not seem to preclude curative resection. The findings support an aggressive attitude toward local diagnosis and surgical treatment in ZES patients, but they also stress the need for improvements in methods for localizing tumors.

Entities:  

Mesh:

Year:  1993        PMID: 8362528     DOI: 10.1007/bf01655105

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

1.  THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES.

Authors:  E H ELLISON; S D WILSON
Journal:  Ann Surg       Date:  1964-09       Impact factor: 12.969

2.  Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.

Authors:  L Bardram; F Stadil
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 3.  Gastrins in serum. A review of gastrin radioimmunoanalysis and the discovery of gastrin heterogeneity in serum.

Authors:  J F Rehfeld
Journal:  Scand J Gastroenterol       Date:  1973       Impact factor: 2.423

4.  Production and evaluation of antibodies for the radioimmunoassay of gastrin.

Authors:  J F Rehfeld; F Stadil; B Rubin
Journal:  Scand J Clin Lab Invest       Date:  1972-10       Impact factor: 1.713

5.  Preparation of 125 I-labelled synthetic human gastrin I for radioimmunoanalysis.

Authors:  F Stadil; J F Rehfeld
Journal:  Scand J Clin Lab Invest       Date:  1972-12       Impact factor: 1.713

6.  Gel filtration studies on immunoreactive gastrin in serum from Zollinger-Ellison patients.

Authors:  J F Rehfeld; F Stadil
Journal:  Gut       Date:  1973-05       Impact factor: 23.059

7.  Biochemical localization of pancreatico-enteric endocrine tumours.

Authors:  S Ingemansson
Journal:  Scand J Gastroenterol Suppl       Date:  1979

8.  The gastrinoma triangle: operative implications.

Authors:  B E Stabile; D J Morrow; E Passaro
Journal:  Am J Surg       Date:  1984-01       Impact factor: 2.565

9.  Resection of gastrinomas.

Authors:  C W Deveney; K E Deveney; D Stark; A Moss; S Stein; L W Way
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

10.  Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome.

Authors:  S Bonfils; J H Landor; M Mignon; P Hervoir
Journal:  Ann Surg       Date:  1981-12       Impact factor: 12.969

View more
  3 in total

Review 1.  [Multiple endocrine neoplasia Type I. Diagnosis and therapy in a case with classical family history].

Authors:  R Lamberts; M Gregor
Journal:  Med Klin (Munich)       Date:  1999-08-15

2.  Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.

Authors:  Weihua Kong; Max Benjamin Albers; Jerena Manoharan; Joachim Nils Goebel; Peter Herbert Kann; Moritz Jesinghaus; Detlef Klaus Bartsch
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

Review 3.  Surgical management of pancreatic endocrine tumors.

Authors:  Volker Fendrich; Jens Waldmann; Detlef K Bartsch; Peter Langer
Journal:  Nat Rev Clin Oncol       Date:  2009-06-09       Impact factor: 66.675

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.